Nippon Shinyaku Co., Ltd. - SIC # 200 -

Ticker Exchange SIC # Website Latest Ticker
NPPNY Over the counter 200 www.nippon-shinyaku.co.jp

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nippon Shinyaku Co., Ltd.

Regenxbio Shares Rise After Positive Duchenne Trial Results - May 14th, 2026 8:09 am
Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus - May 13th, 2026 6:18 am
Capricor Therapeutics Q1 Earnings Call Highlights - May 12th, 2026 4:08 pm
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 12th, 2026 2:05 pm
Nippon Shinyaku (TSE:4516): Exploring Valuation After Recent Share Price Fluctuations - Nov 10th, 2025 8:13 pm
Regenxbio Inc (RGNX) Q3 2025 Earnings Call Highlights: Strong Financial Position and Strategic ... - Nov 6th, 2025 12:08 pm
Nippon Shinyaku Selects LifeSphere® Safety - Oct 27th, 2025 5:00 pm
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress - Oct 14th, 2025 5:13 am
Buloxibutid Receives Orphan Drug Designation in Japan for the Treatment of Idiopathic Pulmonary Fibrosis - Sep 30th, 2025 12:50 am
Nippon Shinyaku (TSE:4516): Valuation Insights as Fundamental Drivers Face Investor Scrutiny - Sep 9th, 2025 7:01 am
FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis - Sep 9th, 2025 5:13 am
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy - Jul 11th, 2025 4:30 am
NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases - Jul 1st, 2025 7:13 am